Cecilia Oliveri

Dr. Cecilia Oliveri

University of Messina, Messina, Sicilia, Italy
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
COCecilia Oliveri
Cecilia Oliveri
AXAnastasia Xourafa
Anastasia Xourafa
RARita Maria Agostino
Rita Maria Agostino
VCValentina Corigliano
Valentina Corigliano
ABAntonino Botindari
Antonino Botindari
Antonino CatalanoAntonino Catalano
Antonino Catalano
Background/Objectives: Platelets play a role in bone metabolism and fracture healing. This study aimed to investigate the association between platelet indices and the derived systemic immune inflammation index (SII) with fracture risk in postmenopausal women. Methods: Platelet count, mean platelet volume, platelet distribution width (PDW), platelet crit, percentage of large platelets (P-LCR), platelet–lymphocyte ratio, and the SII, calculated as (NxP)/L, where N, P, and L represented neutrophils, platelets and lymphocytes counts, respectively, were evaluated. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry. Results: A total of 124 women (mean age 68.4 ± 9 years) were stratified into two groups based on the median platelet count; the “lower platelet count group” (n = 58) had a count of 200,000 (174,000 to 226,000), while the “higher platelet count group” (n = 66) had a count of 281,500 (256,500 to 308,500). The higher platelet count group showed a higher hip fracture risk (7.4 vs. 4.5%, p = 0.08) and lower lumbar spine BMD (0.773 vs. 0.83 gr/cm2, p = 0.03). By dividing the participants into two groups with higher SSI (950,848.6 ± 746,097.99) (n = 61) and lower SII (355,751.2 ± 88,662.6) (n = 63), the group with the higher SII showed the higher hip fracture risk (7.4 vs. 3.6%, p = 0.01). Univariate regression analysis revealed correlations between chronological age and PDW (r = 0.188, p = 0.047), and P-LCR (r = 0.208, p = 0.03), as well as associations between vitamin D status and P-LCR (r = −0.301, p = 0.034), and between SII and hip fracture risk (r = 0.12, p = 0.007). Conclusions: Platelet count and SII were associated with fracture risk in postmenopausal women undergoing osteoporosis assessment. Given their reproducibility and cost-effectiveness, these markers warrant further investigation in future prospective studies focused on bone fragility.

9 July 2025 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
GBGiada Barresi
Giada Barresi
COCecilia Oliveri
Cecilia Oliveri
NMNunziata Morabito
Nunziata Morabito
Herbert Ryan MariniHerbert Ryan Marini
Herbert Ryan Marini
AXAnastasia Xourafa
Anastasia Xourafa
Antonino CatalanoAntonino Catalano
Antonino Catalano

19 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Antonino CatalanoAntonino Catalano
Antonino Catalano
COCecilia Oliveri
Cecilia Oliveri
GNGiuseppe Natale
Giuseppe Natale
RARita Maria Agostino
Rita Maria Agostino
Giovanni SquadritoGiovanni Squadrito
Giovanni Squadrito
Domenico SantoroDomenico Santoro
Domenico Santoro
Background/Objectives: Renal function influences bone metabolism, as kidney failure can increase the risk of fractures. Denosumab is an approved osteoporosis treatment, but its efficacy in relation to renal function has not yet been studied in real-life scenarios. This study aimed to investigate the denosumab-induced change in bone mineral density (BMD) according to kidney function. Methods: A retrospective analysis was conducted at the outpatient clinic in postmenopausal women receiving denosumab (60 mg subcutaneously administered every 6 months). The glomerular filtration rate (eGFR) was measured by the 2021 CKD-EPI equation and patients were stratified for eGFR categories. BMD was measured by dual-energy X-ray absorptiometry. Results: 128 women (mean age 70.3 ± 9.4 years) were recruited. The mean denosumab treatment duration was 3.9 ± 1.4 years and all the participants had improved BMD values. In stepwise multiple regression analysis—after controlling for age, BMI, and treatment duration—the eGFR value (ß = −0.11, SE 0.04, p = 0.01) was independently associated with the lumbar spine BMD change. The same association remained when the eGFR categories were considered (ß = 3.564, SE 1.29, p = 0.007). In addition, after controlling for BMI and the duration of denosumab treatment, age (ß = −0.7915, SE 0.37, p = 0.03) and eGFR (ß = −0.3257, SE 0.1567, p = 0.04) were found to be associated with femoral neck BMD change. The association remained when considering eGFR categories (ß = 8.7339, SE 4.29, p = 0.04). Conclusions: This retrospective study suggests that eGFR is associated with denosumab efficacy in postmenopausal women treated for osteoporosis.

5 May 2025 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
COCecilia Oliveri
Cecilia Oliveri
AXAnastasia Xourafa
Anastasia Xourafa
NMNunziata Morabito
Nunziata Morabito
AGAdele Di Giovanni
Adele Di Giovanni
ELElisa Lupo
Elisa Lupo
Antonino CatalanoAntonino Catalano
Antonino Catalano
Background: Aging is associated with deterioration of muscle and bone health, resulting in increased fragility fracture risk. It is not known whether muscle mass and strength could impact the osteoporosis pharmacological response. Aim: The aim of this study was to analyze the association between muscle mass and strength with the response to denosumab in osteoporosis. Methods: Postmenopausal women at high fracture risk receiving denosumab (60 mg subcutaneously administered every 6 months) were considered. The likelihood of sarcopenia was estimated by administering the SARC-F questionnaire, muscle mass and performance were assessed by measuring calf circumference (CC) and hand grip strength, respectively. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry. Results: 130 women (age 70.2 ± 9.4 years) were recruited. Baseline BMD T-score values were − 2.6 ± 1.1 SD and − 2.3 ± 0.7 SD at lumbar spine and femoral neck, respectively; while CC and grip strength were 31.9 ± 2.9 cm and 22.7 ± 6.7 kg, respectively. The SARC-F score was associated with the 10-year probability of major osteoporotic fracture (r = 0.21, p < 0.05). The CC was positively associated with the T-score values of both lumbar spine (r = 0.262, p = 0.034) and femoral neck (r = 0.359, p = 0.004). Denosumab administration (treatment duration 43 months), lead to BMD improvement by + 9.6% at the lumbar spine and + 7.3% at the femoral neck (pall < 0.05). After adjustment for comorbidities, fracture risk and treatment duration, the CC (β = 1.76, SE = 0.82, p = 0.03) and the baseline femoral BMD (β = − 94.19, SE = 26.09, p = 0.0009) were independently associated with femoral BMD gain over time. Conclusion: In postmenopausal osteoporotic women, the CC was positively and independently associated with denosumab treatment response.

12 March 2026 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
CAClelia Asero
Clelia Asero
COCecilia Oliveri
Cecilia Oliveri
MFMaria Stella Franzè
Maria Stella Franzè
AGAdele Di Giovanni
Adele Di Giovanni
RFRoberto Filomia
Roberto Filomia
ICIrene Cacciola
Irene Cacciola

22 September 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
COCecilia Oliveri
Cecilia Oliveri
AXAnastasia Xourafa
Anastasia Xourafa
NMNunziata Morabito
Nunziata Morabito
AGAgostino Gaudio
Agostino Gaudio
IPIlaria Politi
Ilaria Politi
Antonino CatalanoAntonino Catalano
Antonino Catalano
Context: Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear. Objective: To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH. Methods: This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25 000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers—alkaline phosphatase, osteocalcin, and C-terminal telopeptide of type I collagen—were measured every 6 months. Results: Thirty patients were statin users and 74 were nonusers. Statin users experienced lumbar spine BMD gain from 0.71 ± 0.16 to 0.79 ± 0.14 g/cm² (P = .01) and a trend toward femoral neck improvement from 0.53 ± 0.24 to 0.62 ± 0.12 g/cm² (P = .07). Nonusers also showed a lumbar spine BMD rise from 0.70 ± 0.10 to 0.77 ± 0.11 g/cm² (P = .001), with no significant femoral neck BMD change from 0.60 ± 0.11 to 0.58 ± 0.15 g/cm² (P = .5). At the end of the observation period, C-terminal telopeptide of type I collagen levels were significantly lower in statin users compared to nonusers (0.37 ± 0.29 vs 0.66 ± 0.47 ng/mL, P = .007). Conversely, no significant intergroup differences were observed for alkaline phosphatase and osteocalcin throughout the observation period. Conclusion: Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, but it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.